Skip to content

Press Releases

Updates on ProBioGen and currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines. 

ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

Berlin, Germany – January 18, 2023 ProBioGen is announcing another important clinical milestone for its proprietary viral vector and vaccine production cell line AGE1.CRpIX®. Our..

Read More

ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology

Berlin, Germany – January 10, 2023 ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology...

Read More

ProBioGen Co-Develops New Freedom™ ExpiCHO-S™ Cell Line Development Kit

Berlin, Germany – October 27, 2022 Following the success of the Gibco™ Freedom™ CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to..

Read More

ProBioGen Celebrates "A New Dawn in Biotechnology"

Symposium Honors Chief Scientific Officer, Dr. Volker Sandig Berlin, Germany – September 30, 2022 The biotechnology firm ProBioGen held the symposium "A New Dawn in Biotechnology:..

Read More

ProBioGen Receives Employer of the Future and Top Service Awards

Biopharma Company Recognized at DIGITAL X 2022 Berlin, Germany – September 13, 2022 Today, the Berlin-based biopharmaceutical company ProBioGen received the Employer of the Future..

Read More

ProBioGen and City of Hope Announce Commercial License Agreement to Use AGE1.CR.pIX® Vaccine Manufacturing Platform for Cytomegalovirus (CMV) Vaccine

Berlin, Germany and Los Angeles, USA, September 7, 2022 ProBioGen and City of Hope, one of the largest cancer research and treatment organizations in the United States, announced..

Read More

ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated Project from Cell Line Development to GMP Manufacturing

Berlin, Germany and Cambridge, MA, USA, August 17, 2022 ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of..

Read More

ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)

Sep 16, 2025

ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)

Sep 16, 2025

ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services

May 7, 2025

GlymaxX®-Enhanced Antibody Now Commercially Available for Innovative Cancer Therapy

Apr 17, 2025

Dr. Alfred Merz Appointed Chief Executive Officer of ProBioGen

Mar 31, 2025

ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

Mar 6, 2025

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio

Feb 4, 2025

ProBioGen Expands Protein and Viral Manufacturing to Drive Continued Growth

Jan 7, 2025

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Change in Management

Apr 30, 2024

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever

Mar 27, 2024

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

Mar 13, 2024

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology

Dec 14, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Sep 26, 2023

Press Contact

probiogen-sarah-wandrey

Sarah Wandrey

Corporate Communications

Phone: +49 (0) 30 3229 35 144
Email: press@probiogen.de

ProBioGen News 

Join our news and always be up-to-date.